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Summary 
One hundred sixteen eligible patients with metastatic cancer to the brain were randomized to receive either 
radiotherapy 3000 rad / !0  fractions (treatment l) or the same radiotherapy plus metronidazole 6 g m / m  2 
(treatment 2). One hundred eleven patients were either fully or partially evaluable. The response rates 
(CR + PR) and survival showed no significant differences between treatments. Treatment 1: CR + PR 24%, 
median survival 14 weeks, Treatment  2: CR + PR 27%, median survival 12 weeks. There were no differences 
observed in response rates based on primary tumor  site, neurologic performance status, or extent of 
metastatic disease. Metronidazole therapy was associated with substantial nausea and vomiting but no 
neurotoxicity was observed. Oral metronidazole given every other day during radiation therapy provided no 
clinical benefit for patients with brain metastases compared to radiotherapy alone. 
Introduction 
Improvements  in cancer therapy have resulted in 
longer survival in many patients with various forms 
of malignancy. An unfortunate consequence of this 
improved survival has been the observation of an 
increase in metastatic disease to the brain (1-3). 
Autopsy studies have shown that as many as 
18-22% of patients dying of cancer have intracran- 
ial metastases representing over 80 000 patients per 
year in the USA (4-6). 
Treatment  of metastatic cancer to the brain pres- 
ents an important  palliative problem that has yet to 
result in substantial survival benefit to the patient 
(7). Several retrospective studies (8, 9, 10) and three 
prospective randomized trials reported by the Ra- 
diation Therapy Oncology Group ( l l ,  12) have 
demonstrated the value of whole brain irradiation. 
There also may be some value in resecting solitary 
lesions prior to irradiation (6, 13). 
Even with adequate brain irradiation, 50-60% of 
patients with brain metastases still die from this 
complication (11, 12). Thus, more effective treat- 
ment is needed. Brain metastases are frequently 
large masses with areas of necrosis and presumably 
contain a large fraction of hypoxic cells which are 
relatively radioresistant. Electron-affinic radio- 
sensitizers, such as metronidazole, have been shown 
both in vitro and in vivo to enhance radiation sensi- 
tivity of hypoxic cells relative to euoxic cells (14). In 
a randomized trial, radiation plus metronidazole 
was found to be superior to radiation alone in the 
treatment of glioblastoma multiforme (15). Based 
on that experience the Southwest Oncology Group 
(SWOG) conducted a controlled clinical trial eva- 
luating the effectiveness of metronidazole as a radi- 
osensitizer in the treatment of brain metastases. 
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Materials and methods 
Between July 1978 and May 1982, 25 SWOG 
institutions entered 127 patients on study 7811. 
Eligibility requirements included the following: 
histologic proof  of malignancy, clinical documen- 
tation of brain metastases by isotope or CT brain 
scan, neurological symptoms, no prior cranial radi- 
ation therapy, expected survival of at least 4 weeks, 
and informed consent in accordance with institu- 
tional policy. All patients were adults. Systemic 
chemotherapy with agents known to cross the 
blood brain barrier such as nitrosoureas, procarba- 
zine, DTIC,  or high dose methotrexate was not 
allowed. 
Patients were stratified according to the follow- 
ing: site of primary cancer (breast, lung, other); 
concomitant chemotherapy (yes or no); neurologic 
status (1 & 2 vs 3 & 4); measurable or nonmeasura- 
ble intracranial disease and extent of metastases. 
They were randomly assigned to either radiation 
therapy alone treatment 1 or radiation therapy plus 
metronidazole, treatment 2. 
Treatment 
To control for the known palliative benefit of 
corticosteroids, all patients were given dexametha- 
sone 10 mg/m2/day  in divided doses during the 
course of radiotherapy. The drug was then tapered 
and discontinued. If  it was necessary to begin ste- 
roid therapy again, it was recorded on the data 
sheets. 
Radiation therapy 
All patients were given whole brain radiation 
through lateral ports encompassing the entire in- 
tracranial contents with both ports treated each 
day. The total dose of 3000 rads calculated at the 
midplane along the central axis was given in 10 
daily fractions using megavoltage equipment or 
6°Co units. 
Metronidazole 
Patients assigned to metronidazole received 
6 g in /m 2 (maximum dose 10 gin) in a single dose on 
treatment days 1, 3, 5, 7 and 9. The drug was given 
orally 1-4 hours preceding radiation therapy and at 
least 2-3 hours following the last meal for more 
dependable absorption. Anti-emetics were given 
prior to the metronidazole to control nausea and 
vomiting. 
Study parameters and criteria for response 
All patients were followed weekly by history and 
physical examination to determine neurologic func- 
tion and performance status. In addition, complete 
blood counts and chemistry tests including electro- 
lytes, renal function, and liver function were moni- 
tored. All patients also had a pre- and post-radio- 
therapy brain isotope or CT scan. These tests were 
repeated every 4-8 weeks during follow-up. All pa- 
tients remained on study until death and an attempt 
was made to determine if death was due to the brain 
metastases or systemic disease. 
The patients were evaluated for response accord- 
ing to the following criteria: 
Complete response: complete disappearance of 
intracranial disease on isotope or CT brain scan; 
improvement  of neurologic function by at least I 
level and discontinuation of steroids. 
Partial response: reduction by 50% or more of 
the product of perpendicular diameters of the 
metastatic disease measured by isotopes or CT 
brain scan: stable or improved neurologic func- 
tion and reduced or discontinued steroids. 
Stable disease: no significant change in size of 
brain metastases or change in neurologic func- 
tion. 
Progressive disease: increase in size of brain 
metastases and deterioration of neurologic func- 
tion. 
Statistical analyses 
Survival curves were estimated by the Kaplan-  
Meier technique (16) and compared by the two- 
tailed Gehan's tests (17) and logrank tests (18). 
Response rates and patient characteristics were 
compared using ordinary chi square tests. 
Results 
One hundred twenty-seven patients were entered 
on this study. Of these, 116 were eligible with 111 
fully or partially evaluable. The non evaluable cases 
included 6 with inadequate data submission; 8 who 
were found unacceptable violations at radiation 
therapy evaluation; and 2 with failure to receive 
metronidazole. The patient characteristics of the 
fully and partially evaluable patients are shown in 
Table 1. No evidence of statistically significant im- 
Table 1. Patient characteristics. 
Characteristics Radiation 




Patient no. 54 
Age < 60 years 29 
60 or more years 25 





Neurologic function 1-2 44 
3 4 10 
Metastatic extent 
Brain only 27 












Table 2. Response rate and duration. 
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balance in the assignment of patients to treatment 
was found. 
The complete response and partial response rates 
were similar for both treatments (CR + PR p 
value = .958). There was no statistically significant 
association between the response rates (CR + PR) 
and the primary site, neurologic function, metastat- 
ic extent age or sex. Patients with breast cancer had 
a higher CR rate but this was not quite statistically 
significant (p-value = .067). These data are listed in 
Table 2. 
Although the median duration of the responses 
(CR + PR) was 18 weeks for radiation plus metro- 
nidazole compared to 11 weeks for radiation alone, 
the overall response duration analyses showed no 
significant difference (Gehan p-value = .442). The 
four responding patients with breast cancer had a 
longer duration of response (30 weeks median) than 
those with lung cancer (I0 weeks median) (Gehan 
p-values .063). Patients with brain metastases only 
had no significantly longer response durations than 
those with both brain and systemic metastases. 
There were so few patients (5) with poor neurologic 
function (class 3 + 4) that responded that the com- 
parison of response duration versus neurologic 
function is less valid but those with severe impair- 
ment had a median response duration of only 7 
weeks compared to 18 weeks for neurologic classes 




Radiation 54 7 
Radiation + metro. 57 9 
Age 
Under 60 68 l0 
60 or more 43 5 
Primary site 
Breast 13 23 
Lung 69 4 
Other 29 10 
Neurologic function 
1 + 2  81 8 
3 + 4  19 I0 
Metastatic extent 
Brain only 55 5 
Systemic + brain 56 11 
17 24 .958 11 .442 
18 27 18 
21 31 .133 23 .047 
12 17 9 
8 31 30 
20 24 .886 10 .063 
14 24 18 
18 26 .857 18 .347 
14 24 7 
22 27 .784 10 .710 
13 24 20 
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l + 2. There was a marked difference in remission 
duration based on age with those under 60 years 
having longer response durations (Gehanp-value = 
.047). These data are also listed in Table 2. 
The survival of  patients treated with radiation 
alone was not significantly different from those 
treated with radiation plus metronidazole.  These 
survival curves are illustrated in Fig. 1. Survival 
based on primary site of malignancy did show a 
significant difference emerging after about 13 weeks 
when patients with breast cancer were compared to 
those with lung cancer (Logrank p-value = .048). 
This is shown in Fig. 2. Patients with minimal neu- 
rological impairment (neurologic class 1 + 2) had 
some advantage in survival when compared to 
those with marked symptoms (neurologic class 3 + 
4) but this difference was not statistically significant 
(Logrank p-value = .171) (Fig. 3). Regarding the 
relation of survival duration and extent of metastat- 
ic disease no significant difference was observed 
between patients with only brain metastases and 
those with brain plus systemic metastases (Gehan 
p-value = .470) as is seen in Fig. 4. Fifty patients 
(45%) were judged by the investigators to have died 
secondary to their brain metastases. Forty seven 
(42%) died from systemic malignancy and 14 (13%) 
from both or unknown reasons. Patients aged 
under 60 years survived significantly longer than 
those age 60 years or more (Gehanp-value  = .037) 
as shown in Fig. 5. 
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Fig. 2. Survival time based on primary site for all evaluable 
patients regard less of treatment. There is a significant difference 
based on the Logrank analysis for breast primary versus lung 
primary (P-value = .048). 
All patients developed alopecia and some radia- 
tion scalp reaction was noted. These were not signif- 
icantly worse in patients receiving metronidazole. 
The major toxicity observed was moderate to se- 
vere nausea and vomiting in patients receiving 
metronidazole.  Eighty-two percent of the 57 pa- 
tients evaluated on treatment 2 were recorded as 
completing all the prescribed metronidazole.  The 
other ten patients completed 3 or 4 of  the 5 doses. 
The nausea and vomiting w a s  poorly controlled 
1.00- 
.90-  
. e 0 -  
, 70 -  
.60 - 
~: .s0- o 







" ~ ~ T R O N I D A Z O  LE 
r i i i i i t i 
15 30 45 60 75 90 105 120 
WEEKS 
Ftg. 1. Survival time for all evaluable patients. Treatment 1-ra- 
diation only, Treatment 2-radiation plus metronidazole. N o  
significant difference is observed (P-value = .802).  
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Fig. 3. Survival time for all evaluable patients based on entering 
neurologic function. No significant difference is observed ( P -  
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Fig. 4. S u r v i v a l  t ime f o r  al l  eva luab ]e  pa t ien ts  based on  e x t e n t  o f  
metastases.  N o  s i gn i f i can t  d i f f e rence  is obse rved  ( P - v a l u e  = 
.470). 
with anti-emetics and clearly is dose limiting with 
the oral route for this agent. This was limited in 
time to the day of therapy and did not persist 
beyond the treatment course. No peripheral neu- 
ropathies were seen in the group receiving metro- 
nidazole. No other adverse effects were detected. 
Toxicity data are shown in Table 3. 
Discussion 
Metastatic disease to the brain is an ominous 
occurrence. Almost all patients become sympto- 
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Fig. 5. Survival time for all evaluable patients based on age. 
Patients less than 60 years survived significantly longer than those 
60 years or older (P-value = .037). 
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Table 3. Toxicity. 
Toxicity Radiation Radiation plus 
metronidazole 
Nausea/vomiting 3.2% 51% 
Myelosuppression* 12.9% 0% 
Neuropathy 3.2% 0% 
* Some patients received concomitat chemotherapy with cyclo- 
phosphamide, vincristine, and fluorouracil. 
matic from it and irregardless of current therapies, 
the majority will die from this complication within 
3-4 months. It is clear that conventional radiother- 
apy can result in palliative benefit but that it will not 
result in long term disease control for the majority 
of patients (7 12). Clearly new therapies are needed. 
This randomized clinical trial demonstrates that 
oral metronidazaole given every other day was not 
of any value when combined with conventional 
radiation 300 rad fractions in 10 treatments for 
treatment of brain metastases compared to radia- 
tion alone. Unfortunately other clinical trials using 
misonidazole have also failed to have significant 
impact on survival (19, 20). 
The dose of metronidazole used in this trial re- 
sulted in moderate to severe nausea and vomiting 
which was significant enough to be disabling and 
dose limiting. If further studies using this agent are 
undertaken with higher dose some alternate sche- 
dule or route of administration will be necessary 
such as intravenous therapy. 
Other ideas under investigation for the treatment 
of brain metastases such as intra-arterial chemo- 
therapy (21), surgical resection (13), hyperthermia 
(22), blood brain barrier disruption (23) followed 
by chemotherapy may be of benefit and should be 
persued. One other possible approach to this prob- 
lem would seem to be prophylaxis such as is used 
with programs designed for small cell lung cancer 
and leukemia. 
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